Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

Inclusion criteria

• age 18-70 years old, gender is not limited;
• Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver;
• Imaging evaluable tumors with safe access to puncture;
• The number of half liver tumors ≤3 and the size of each tumor ≤3 cm;
• ECOG PS score ≤2 points, expected survival > 3 months.

Exclusion criteria

• Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice;
• The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume;
• Expected survival < 3 months;
• serious heart, lung, liver and kidney dysfunction and coagulation dysfunction;
• Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study;
• refractory ascites, pleural fluid or bad fluid;
• Pregnancy or breastfeeding;
• The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.